JP2005505236A5 - - Google Patents

Download PDF

Info

Publication number
JP2005505236A5
JP2005505236A5 JP2002559550A JP2002559550A JP2005505236A5 JP 2005505236 A5 JP2005505236 A5 JP 2005505236A5 JP 2002559550 A JP2002559550 A JP 2002559550A JP 2002559550 A JP2002559550 A JP 2002559550A JP 2005505236 A5 JP2005505236 A5 JP 2005505236A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002559550A
Other versions
JP2005505236A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/049413 external-priority patent/WO2002059263A2/en
Publication of JP2005505236A publication Critical patent/JP2005505236A/ja
Publication of JP2005505236A5 publication Critical patent/JP2005505236A5/ja
Pending legal-status Critical Current

Links

JP2002559550A 2000-12-19 2001-12-19 ヒト化免疫系を含むトランスジェニック動物 Pending JP2005505236A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25659100P 2000-12-19 2000-12-19
PCT/US2001/049413 WO2002059263A2 (en) 2000-12-19 2001-12-19 Transgenic animals comprising a humanized immune system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008196379A Division JP2009034106A (ja) 2000-12-19 2008-07-30 ヒト化免疫系を含むトランスジェニック動物

Publications (2)

Publication Number Publication Date
JP2005505236A JP2005505236A (ja) 2005-02-24
JP2005505236A5 true JP2005505236A5 (ja) 2005-08-04

Family

ID=22972817

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002559550A Pending JP2005505236A (ja) 2000-12-19 2001-12-19 ヒト化免疫系を含むトランスジェニック動物
JP2008196379A Pending JP2009034106A (ja) 2000-12-19 2008-07-30 ヒト化免疫系を含むトランスジェニック動物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008196379A Pending JP2009034106A (ja) 2000-12-19 2008-07-30 ヒト化免疫系を含むトランスジェニック動物

Country Status (8)

Country Link
US (1) US20030093818A1 (ja)
EP (1) EP1409646B1 (ja)
JP (2) JP2005505236A (ja)
AU (1) AU2002246733B2 (ja)
CA (1) CA2432133C (ja)
DK (1) DK1409646T3 (ja)
ES (1) ES2389251T3 (ja)
WO (1) WO2002059263A2 (ja)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1476469B1 (en) 2002-01-25 2015-11-18 Novo Nordisk A/S Monoclonal antibodies against extracellular loops of c5ar
JP5478003B2 (ja) * 2003-07-10 2014-04-23 アンスティチュ パストゥール ヒトの主要組織適合複合体（ｍｈｃ）の表現型を有するトランスジェニックマウス、その実験のための使用および応用方法
US7663017B2 (en) 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
EP1701611B1 (en) * 2003-12-24 2011-05-18 G2 Inflammation Pty Ltd Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar
CA2555185C (en) 2004-02-06 2020-03-24 Morphosys Ag Anti-cd38 human antibodies and uses therefor
US7994298B2 (en) 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
US20090298195A1 (en) 2005-01-05 2009-12-03 F-Star Biotechnologische Forschungs-Und Entwicklun Gseges M.B.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
RU2425841C2 (ru) 2005-10-12 2011-08-10 МорфоСис АГ Получение и анализ полностью человеческих лечебных антител-производных hucal gold, специфичных к человеческому cd38
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
JP5162587B2 (ja) 2006-08-22 2013-03-13 ジーツー インフラメイション プロプライエタリー リミテッド 改良された特性を持つ坑−Ｃ５ａＲ抗体
US8921279B2 (en) 2007-06-26 2014-12-30 F-Star Biotechnologische Forschungs—und Entwicklungsges. m.b.H Display of binding agents
BRPI0907532A2 (pt) 2008-02-20 2015-07-28 G2 Inflammation Pty Ltd Anticorpos anti-c5ar humanizados
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
US20090328240A1 (en) * 2008-06-24 2009-12-31 Sing George L Genetically modified mice as predictors of immune response
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US20120204278A1 (en) 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
EP2564695B1 (en) * 2009-07-08 2015-04-15 Kymab Limited Animal models and therapeutic molecules
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
DK2718322T3 (en) 2011-06-06 2018-12-03 Novo Nordisk As THERAPEUTIC ANTIBODIES
WO2013033626A2 (en) 2011-08-31 2013-03-07 Trustees Of Dartmouth College Nkp30 receptor targeted therapeutics
CN106995822B (zh) 2011-09-19 2021-06-29 科马布有限公司 定制供人类使用的抗体、可变结构域和链
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
ES2651517T3 (es) 2011-10-28 2018-01-26 Regeneron Pharmaceuticals, Inc. Ratones con complejo mayor de histocompatibilidad modificado genéticamente
RS57893B1 (sr) * 2011-10-28 2019-01-31 Regeneron Pharma Miševi sa genetski modifikovanim receptorom t ćelija
US9591835B2 (en) 2011-10-28 2017-03-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
EP4052572A1 (en) 2011-10-28 2022-09-07 Regeneron Pharmaceuticals, Inc. Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
CN104395344B (zh) 2012-05-07 2019-08-13 达特茅斯大学理事会 抗b7-h6抗体、融合蛋白及其使用方法
GB2508414A (en) * 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
EP2958938B1 (en) 2013-02-20 2019-04-17 Regeneron Pharmaceuticals, Inc. Mice expressing humanized t-cell co-receptors
CA2900824A1 (en) * 2013-02-22 2014-08-28 Regeneron Pharmaceuticals, Inc. Mice expressing humanized major histocompatibility complex
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
NL2013554B1 (en) 2013-10-01 2016-01-08 Kymab Ltd Animal models and therapeutic molecules.
EP3067366A1 (en) * 2015-03-13 2016-09-14 Max-Delbrück-Centrum Für Molekulare Medizin Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1
CN113349159B (zh) 2015-04-06 2022-11-11 瑞泽恩制药公司 非人动物中的人源化t细胞介导的免疫应答
MA44907A (fr) * 2015-09-11 2018-07-18 Agenus Inc Cellules hôtes génétiquement modifiées et leurs procédés d'utilisation
JP7058223B2 (ja) 2016-04-15 2022-04-21 メモリアル スローン ケタリング キャンサー センター トランスジェニックｔ細胞及びキメラ抗原受容体ｔ細胞組成物及び関連方法
WO2018233608A1 (en) * 2017-06-19 2018-12-27 Beijing Biocytogen Co., Ltd NON-HUMAN ANIMAL GENETICALLY MODIFIED TO CD28 HUMAN OR CHIMERIC
CN109136261B (zh) 2017-06-19 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化cd28基因改造动物模型的制备方法及应用
WO2020018715A1 (en) 2018-07-17 2020-01-23 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
JP7422365B2 (ja) * 2018-07-26 2024-01-26 国立大学法人京都大学 外来抗原レセプター遺伝子導入細胞の製造方法
WO2023070126A1 (en) * 2021-10-22 2023-04-27 Regents Of The University Of Minnesota Genetically engineered t cell receptors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US256591A (en) 1882-04-18 Adding-machine
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0663952A4 (en) * 1992-09-11 1997-06-11 Univ California TRANSGENIC NON-HUMAN ANIMALS WITH TARGETED INTERRUPTED TRANSDUCTION GENES IN LYMPHOCYTES.
EP1916300A1 (en) * 1995-08-29 2008-04-30 Kirin Pharma Kabushiki Kaisha Chimeric animal and method for producing the same
WO1997032603A1 (en) * 1996-03-05 1997-09-12 The Scripps Research Institute Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens
ES2301183T3 (es) * 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
DE19816129A1 (de) * 1998-04-09 1999-10-14 Dolores Schendel T-Zellrezeptor-Expressionskassette
DE102010004180A1 (de) 2010-01-07 2011-07-14 KAUTEX TEXTRON GmbH & Co. KG, 53229 Tropfenabscheider
US8943086B2 (en) 2012-06-29 2015-01-27 Sap Se Model-based backend service adaptation of business objects

Similar Documents

Publication Publication Date Title
BE2022C531I2 (ja)
BE2022C502I2 (ja)
BE2022C547I2 (ja)
BE2017C057I2 (ja)
BE2017C051I2 (ja)
BE2017C032I2 (ja)
BE2016C051I2 (ja)
BE2015C046I2 (ja)
BE2014C052I2 (ja)
BE2014C036I2 (ja)
BE2014C026I2 (ja)
BE2014C004I2 (ja)
BE2017C050I2 (ja)
JP2002198126A5 (ja)
JP2005505236A5 (ja)
JP2002125090A5 (ja)
BRPI0209186B1 (ja)
BE2014C008I2 (ja)
BRPI0204884B1 (ja)
CH1379220H1 (ja)
BE2016C021I2 (ja)
BE2017C059I2 (ja)
JP2002239096A5 (ja)
JP2001312243A5 (ja)
JP2002237539A5 (ja)